Cite
HARVARD Citation
Seman, L. et al. (n.d.). Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Clinical pharmacology in drug development. 2 (2), pp. 152-161. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Seman, L. et al. (n.d.). Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Clinical pharmacology in drug development. 2 (2), pp. 152-161. [Online].